Home | Welcome to Contract Pharma   
Last Updated Sunday, February 1 2015

Print

Search Results for 'Financial Report: Covance'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published May 2, 2014
Late-Stage revenues up 8% in the quarter Read More »
Published October 30, 2013
Late-Stage revenues up 19% in the quarter Read More »
Published July 31, 2013
Late-Stage revenues up 17% in the quarter Read More »
Published January 25, 2013
Late-Stage revenues up 16% in the quarter Read More »
Published November 6, 2012
Late-stage development revenues up 7% Read More »
Published January 27, 2012
Early and late-stage FY revenues up 11% and 7%, respectively Read More »
Published May 5, 2011
Early Development revenues were $224.0 million (+9%). Read More »
Published April 29, 2010
Early development revenues were $205.0 million (+7%). Read More »
Published January 28, 2010
Early-Stage down, Late-Stage up Read More »
Published April 29, 2008
Covance 1Q Revenues: $434.0 million (+15%) 1Q Earnings: $49.1 million (+26%) Comments: Early development revenues were $202.0 million (+13%) led by growth of toxicology and chemistry services. Operating income increased 16% to $50.6 million.… Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On